{"doi":"10.15420/ecr.2023.40","title":"Dual-pathway Inhibition with Low-dose Aspirin and Rivaroxaban versus Aspirin Monotherapy in Patients with Coronary Artery Disease and Peripheral Artery Disease: Systematic Literature Review and Meta-analysis","abstract":"Background: Low-dose aspirin lowers cardiovascular event risk; dual-pathway inhibition (DPI) using low-dose aspirin with low-dose rivaroxaban may reduce this risk further. A systematic literature review and meta-analysis compared the efficacy, safety and net clinical benefit (NCB) of DPI with aspirin. Methods: PubMed and Embase were searched for randomised controlled trials reporting clinical efficacy, safety and NCB of DPI compared with aspirin alone in patients with coronary artery disease (CAD) and/or peripheral artery disease. Six articles representing four trials were included. Results: DPI versus aspirin alone significantly reduced major adverse cardiovascular events (HR 0.77; 95% CI [0.69-0.87]; p<0.01), increased International Society on Thrombosis and Haemostasis major bleeding events (HR 1.67; 95% CI [1.37-2.02]; p<0.01) and resulted in a significant NCB (HR 0.79; 95% CI [0.70-0.90]; p<0.01). Conclusion: These results underscore the potential benefit of DPI in patients with CAD, including those in the immediate post-acute coronary syndrome stage and with established CAD, as well as patients with peripheral artery disease.","journal":"European Cardiology Review","year":2024,"id":428136,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":13,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9568,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":71977,"name":"Michael J. Blaha","orcid":"0000-0001-5138-9683","position":1,"is_corresponding":false},{"id":1229327,"name":"Rajinder Chawla","orcid":"0009-0008-0263-9971","position":2,"is_corresponding":false},{"id":1229328,"name":"Augusto Lavalle Cobo","orcid":"0000-0002-1257-9211","position":3,"is_corresponding":false},{"id":1229329,"name":"Amit Kishore","orcid":"0000-0002-8051-1593","position":4,"is_corresponding":false},{"id":1176471,"name":"Ángel Lanas","orcid":"0000-0001-5932-2889","position":5,"is_corresponding":false},{"id":970293,"name":"Li Li","orcid":"0000-0001-6301-3544","position":6,"is_corresponding":false},{"id":1229330,"name":"Francesca Santilli","orcid":"0000-0002-4593-905X","position":7,"is_corresponding":false},{"id":1061677,"name":"Oliver Schnell","orcid":"0000-0003-4968-2367","position":8,"is_corresponding":false},{"id":1229331,"name":"Zhongwei Shi","orcid":"0000-0002-9919-0830","position":9,"is_corresponding":false},{"id":84530,"name":"Dirk Sibbing","orcid":"0000-0002-0698-2696","position":0,"is_corresponding":true}],"reference_count":21,"raw_metadata":null,"created_at":"2026-07-19T01:58:57.592578Z","pmid":"38708371","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}